Share

The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data:
News in Numbers

69%

The approximate proportion of CMO high-containment facilities in Europe that can be found in the 5EU and Switzerland

98%

The Philippines Department of Health has recorded that from January to 20 July there was a 98% increase in dengue fever cases on the same period last year

2

The number of Ebola drugs that have shown promise in clinical trials amid the ongoing outbreak in the Democratic Republic of Congo

6

The number of new drugs in the pipeline that address the need for personalised prostate cancer treatments

$20m  

The up-front price that Pharming has agreed to pay to acquire leniolisib, a late-stage pipeline drug aimed at a rare disease of the immune system, from Novartis

Data:
News In Numbers

98%

The Philippines Department of Health has recorded that from January to 20 July there was a 98% increase in dengue fever cases on the same period last year

2

The number of Ebola drugs that have shown promise in clinical trials amid the ongoing outbreak in the Democratic Republic of Congo

69%

The approximate proportion of CMO high-containment facilities in Europe that can be found in the 5EU and Switzerland

6

The number of new drugs in the pipeline that address the need for personalised prostate cancer treatments

$20m 

The up-front price that Pharming has agreed to pay to acquire leniolisib, a late-stage pipeline drug aimed at a rare disease of the immune system, from Novartis

 Novartis benefits from faster China drug approvals

Novartis, the Swiss pharmaceutical company, plans to submit 50 new drug applications in China over the next few years, as it projects faster Chinese drug approvals which could see the country overtake Europe to become its second-largest market.

Source: The Financial Times

China to set up inspection teams to ensure drug safety

China will set up specialized inspection teams of pharmaceutical professionals at central and provincial levels to tighten the supervision and regulation of drug safety, including medical equipment and cosmetics.

Source: Xinhua

 Drugmakers named for breaching UK code

Daiichi-Sankyo, GW Pharmaceuticals, Bayer, Proveca and Otsuka will be named in advertisements following breaches of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.

Source: The Pharma Letter

 AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.

Source: Pharmaphorum

 Allergan's bid to shield Botox manufacturing secrets from competitors backfires

A US International Trade Commission judge has ordered Allergan to turn over details of its Botox manufacturing to Evolus and South Korea-based Daewoong, the makers of rival Jeuveau, as part of an investigation the Irish drugmaker requested in February.

Source: Fierce Pharma

Approvals

 AR-501

Aridis Pharmaceuticals has been granted orphan drug designation for AR-501, its inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.

Source: Cision

Vitrakvi (larotrectinib)

The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi, used to treat solid tumours with a specific gene mutation.

Source: European Pharmaceutical Review

TURALIO (pexidartinib)

The FDA has approved Daiichi Sankyo’s TURALIO for the treatment of select patients with symptomatic tenosynovial giant cell tumour.

Source: Daiichi-Sankyo

Lynparza (olaparib)  

A “game-changing” drug for women living with ovarian cancer has received approval as a first stage treatment on the NHS.

Source: Independent

Share this article